Zaporizhzhya State Medical University

Zaporizhzhya, Ukraine

Zaporizhzhya State Medical University

Zaporizhzhya, Ukraine
Time filter
Source Type

Antypenko L.M.,Zaporizhzhya State Medical University | Kovalenko S.I.,Zaporizhzhya State Medical University | Antypenko O.M.,Zaporizhzhya State Medical University | Katsev A.M.,Crimea State Medical University | Achkasova O.M.,Zaporizhzhya Regional Hospital
Scientia Pharmaceutica | Year: 2013

The novel heterocyclization of 5-(2-aminophenyl)-1N{cyrillic}-tetrazole with potassium ethylxanthogenate or carbon disulfide was proposed. The potassium salt of the tetrazolo[1,5-c]quinazoline-5-thione was subsequently modified by alkylation with proper halogen derivatives to (tetrazolo[1,5-c]quinazolin-5-ylthio)alkyls, N,N-dialkylethylamines, 1-aryl-2-ethanones, 1-(alkyl)aryl-2-ethanols, carboxylic acids, and esters. The structures of all newly synthesized compounds were confirmed by FT-IR, UV-vis, LC-MS, 1H, 13C NMR, and elemental analysis data. The substances were screened for antibacterial and antifungal activities (100 μg) against Escherichia coli, Staphylococcus aureus, Enterobacter aerogenes, Entrococcus faecalis, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Candida albicans. Preliminary bioluminescence inhibition tests against Photobacterium leiognathi Sh1 showed that substances 5.2-5.4, 6.1, 7.1 with ethanone or carboxylic acid substituents showed toxicity against bacteria cells. The substances chosen by the US National Cancer Institute (NCI) were screened for their ability to inhibit 60 different human tumor cell lines, where 2-(tetrazolo[1,5-c]quinazolin-5-ylthio)-1-(4-tolyl)ethanone (5.2), 3-(tetrazolo[1,5-c]quinazolin-5-ylthio)propanoic and related 3-metyl-butanoic acids (6.2, 6.3), and ethyl tetrazolo[1,5-c]quinazolin-5-ylthio)acetate (7.2) showed lethal antitumor activity (1.0 μM) against the acute lymphoblastic leukemia cell line (CCRF-CEM), and substances 5.2 and 6.3 exhibited moderate anticancer properties inhibiting growth of the leukemia MOLT-4 and HL06-(TB) cell lines. The moderate antitumor activity was demonstrated in 1-(2,5-dimethoxyphenyl)-2-(tetrazolo[1,5-c]quinazolin-5-ylthio)ethanone (5.4) against the CNS cancer cell line SNB-75. Comparing the docking mode of the Gefitinib and synthesised substances on the ATP binding site of EGFR, it could be assumed that these compounds might act in the same way. The results of the investigation could be considered as a useful base for future development of potent antimicrobials and antitumor agents among tetrazolo[1,5-c]quinazoline-5-thione S-derivatives. © Antypenko et al.

Slivko E.I.,Zaporizhzhya State Medical University | Bogutskaya G.A.,Zaporizhzhya State Medical University
Neurophysiology | Year: 2017

In tests on healthy volunteers, we examined the effects of voluntary flexion of the elbow joint on the magnitude of the H reflex recorded from the ipsilateral m. soleus and on tonic EMG activity of this muscle. The H reflex was subjected to two-phase modulation; a period of facilitation lasting up to 300 msec was replaced by subsequent long-lasting inhibition. Tonic EMG-activity of the m. soleus induced by moderate voluntary contraction of its antagonist did not undergo significant changes under these conditions. As is supposed, changes in the intensity of background presynaptic inhibition exerted on afferents of the H reflex arc are the reason for the observed shifts in the magnitude of this reflex. © 2017 Springer Science+Business Media, LLC

Antypenko L.M.,Organic Avenue | Solodovnyk V.A.,Zaporizhzhya State Medical University
Dhaka University Journal of Pharmaceutical Sciences | Year: 2017

A simple and low-cost UV-spectrophotometric method has been developed and validated for the quantification of Octopirox in bulk. The linearity was found at 307 ± 1 nm in 10-50 µg/ml solution of ethanol-water (1:3, v:v) with r2 = 0.99. The limit of detection was found to be 1.18 μg/ml, while the limit of quantification was 3.58 μg/ml. The method was validated for linearity, accuracy, precision, range, ruggedness and robustness. © 2017, University of Dhaka. All rights reserved.

Antypenko O.M.,Zaporizhzhya State Medical University | Kovalenko S.I.,Zaporizhzhya State Medical University | Zhernova G..,Zaporizhzhya State Medical University
Scientia Pharmaceutica | Year: 2016

Methods of 1-[2-(1H-tetrazol-5-yl)-R1-phenyl]-3-R2-phenyl(ethyl)ureas and R1-tetrazolo[1,5-c]quinazolin-5(6H)-ones synthesis were designed. IR, LC-MS, 1H-NMR, and elemental analysis data evaluated the structure and purity of the obtained compounds. Different products, depending on the reaction conditions, were distinguished and discussed. The preliminary hypoglycemic activity of 36 synthesized compounds was revealed. Docking studies to 11β-hydroxysteroid dehydrogenase 1, γ-peroxisome proliferator-activated receptor, and dipeptidyl peptidase-4 were conducted. Eight of these substances were further tested on glucocorticoid-induced insulin resistance models, namely glucose tolerance, oral rapid insulin, and adrenalin tests. One of the most active compounds turned out to be tetrazolo[1,5-c]quinazolin-5(6H)-one 3.1, exceeding the reference drugs Metformin (50 and 200 mg/kg) and Gliclazide (50 mg/kg). © Antypenko et al.

Antypenko O.M.,Zaporizhzhya State Medical University | Kovalenko S.I.,Zaporizhzhya State Medical University | Karpenko O.V.,Enamine Ltd.
Synthetic Communications | Year: 2016

A series of tetrazolo[1,5-c]quinazolines were synthesized by [4 + 1]-cyclocondensation of 4-hydrazinoquinazolines with sodium nitrite with good yields. Peculiarities of this reaction were discussed, namely, the influence of halogen on the reaction yield. Hydrolytic cleavage of tetrazolo[1,5-c]quinozoline cycle was studied in order to obtain 2-(1H-tetrazolo-5-yl)anilines. The structures of the compounds were elucidated by 1H NMR, 13C NMR, infrared, mass spectrometry, and elemental analysis. 2016 Copyright © Taylor & Francis Group, LLC

Hauser R.A.,University of South Florida | Olanow C.W.,Mount Sinai School of Medicine | Kieburtz K.D.,University of Rochester | Pourcher E.,Laval University | And 8 more authors.
The Lancet Neurology | Year: 2014

Background: Many patients with Parkinson's disease have motor fluctuations despite treatment with available drugs. Tozadenant (SYN115) is an oral, selective adenosine A2A receptor antagonist that improves motor function in animal models of Parkinson's disease. We aimed to assess the safety and efficacy of tozadenant as an adjunct to levodopa in patients with Parkinson's disease who have motor fluctuations on levodopa. Methods: We did an international, multicentre, phase 2b, randomised, double-blind, placebo-controlled, parallel-group, dose-finding clinical trial of tozadenant in levodopa-treated patients with Parkinson's disease who had motor fluctuations (at least 2·5 h off-time per day). Eligible patients were randomly assigned via a computer-generated randomisation schedule to receive tozadenant 60, 120, 180, or 240 mg or matching placebo twice daily for 12 weeks. All study management, site personnel, and patients were masked to treatment assignment. The primary outcome was change from baseline to week 12 in hours per day spent in the off-state (assessed from Parkinson's disease diaries completed by patients). This study is registered at, number NCT01283594. Findings: Of 420 randomised patients (mean age 63·3 [SD 8·3] years; mean duration of Parkinson's disease 8·7 [4·7] years), 403 provided post-baseline diary data and 337 completed study treatment. Compared with placebo, mean daily off-time was significantly reduced in the combined tozadenant 120 mg twice-daily and 180 mg twice-daily group (-1·1 h, 95% CI -1·8 to -0·5; p=0·0006), the tozadenant 120 mg twice-daily group (-1·1 h, -1·8 to -0·4; p=0.0039), and the tozadenant 180 mg twice-daily group (-1·2 h, -1·9 to -0·4; p=0·0039). The most common adverse events in these groups were dyskinesia (seven [8%] of 84 patients in the placebo group, 13 [16%] of 82 in the 120 mg twice-daily group, and 17 [20%] of 85 in the 180 mg twice-daily group), nausea (three [4%], 9 [11%], and ten [12%]), and dizziness (one [1%], four [5%], and 11 [13%]). Tozadenant 60 mg twice daily was not associated with a significant reduction in off-time, and tozadenant 240 mg twice daily was associated with an increased rate of discontinuation because of adverse events (17 [20%] of 84 patients). Interpretation: Tozadenant at 120 or 180 mg twice daily was generally well tolerated and was effective at reducing off-time. Further investigation of tozadenant treatment in phase 3 trials is warranted. Funding: Biotie Therapies. © 2014 Elsevier Ltd.

Novello S.,University of Turin | Scagliotti G.V.,University of Turin | Sydorenko O.,Zaporizhzhya State Medical University | Vynnychenko I.,Sumy State University | And 6 more authors.
Journal of Thoracic Oncology | Year: 2014

Introduction: The phase 3 MONET1 study evaluated motesanib (a small-molecule inhibitor of vascular endothelial growth factor receptors) plus carboplatin/paclitaxel versus placebo plus carboplatin/ paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC). Treatment and enrollment of patients with squamous histology were permanently discontinued following higher early mortality and gross hemoptysis in those with squamous NSCLC who received motesanib. Enrollment of patients with nonsquamous histology was temporarily halted, but resumed following a protocol amendment (Scagliotti et al. J Clin Oncol. 2012;30:2829-2836). Herein, we report data from the squamous cohort. Methods: Patients with stage IIIB/IV or recurrent squamous NSCLC (without prior systemic therapy for advanced disease) received up to six 3-week cycles of chemotherapy (carboplatin, area under the curve 6 mg/L•min/paclitaxel, 200 mg2) and were randomized 1:1 to receive motesanib 125 mg (Arm A) or placebo (Arm B) once daily. The primary end point was overall survival. Results: Three-hundred and sixty patients with squamous NSCLC were randomized (Arm A, n = 182; Arm B, n = 178) between July 2007 and November 2008. Twenty-three patients (13%) in Arm A and 10 (6%) in Arm B had fatal adverse events within the first 60 days of treatment. Among these, six patients in Arm A, but none in Arm B, had fatal bleeding events. At final analysis, serious adverse events had occurred in 47% of patients in Arm A and 29% of patients in Arm B. Median overall survival was similar in Arms A and B (11.1 versus 10.7 months). Conclusions: Motesanib plus carboplatin/paclitaxel had unacceptable toxicity compared with carboplatin/paclitaxel alone in patients with advanced squamous NSCLC. Copyright © 2014 by the International Association for the Study of Lung.

Lezhenko G.,Zaporizhzhya State Medical University
Georgian medical news | Year: 2013

The purpose of this investigation is to determine the role of osteopontin and adiponectin in the formation of arterial hypertension in adolescents with obesity. 67 adolescents with obesity have been examined. Two groups were composed taking into account the state of arterial pressure. The first group included adolescents with obesity and arterial hypertension, the second group - adolescents with obesity and without arterial hypertension. Arterial pressure was measured and serum content of osteopontin, insulin, C-peptid and adiponectin in blood has been determined. The result of the investigation has revealed that in adolescents without arterial pressure the growth of insulin and C-peptid in the serum of blood has been observed; in patients with obesity and arterial hypertension the increase of content of osteopontin and hypoadiponectinemia has been occurred. The revealed changes indicated about the pathogenic role of osteopontin and adiponectin in the formation of arterial hypertension in adolescents with obesity.

Dzyak G.V.,Zaporizhzhya State Medical University | Kolesnyk M.Y.,Zaporizhzhya State Medical University
Kardiologiya | Year: 2014

Purpose: to assess parameters of myocardial deformation and rotation in untreated hypertensive men depending on presence and degree of left ventricular hypertrophy (LVH). Material and methods. We examined 98 hypertensive men aged 51 (46-58) years. Examination included clinical evaluation, conventional transthoracic echocardiography, ambulatory blood pressure monitoring, routine laboratory screening. LV deformation and rotation was studied by two-dimensional speckle tracking echocardiography. Results. In patients without LVH we observed significant decrease of longitudinal strain without changes of rotation. Higher degree of LVH was associated with more pronounced lowering of longitudinal deformation. Severe LVH was characterized by decreased longitudinal, circumferential and radial deformation with compensatory increase of apical LV rotation. Conclusion. Changes of LV deformation are observed in patients with hypertension before LVH formation. This opens new perspectives of early assessment of LV remodeling. Changes of LV deformation are related to degree of LVH.

PubMed | Zaporizhzhya State Medical University
Type: | Journal: Current computer-aided drug design | Year: 2016

The increasing mortality due to antibacterial resistance necessitates the search for novel antimicrobial agents. Hence, series of 1-R-2-([1,2,4]triazolo[1,5-c]quinazoline-2-ylthio)etanon(ol)s were synthesized, evaluated by spectral data and studied against St. aureus, M. luteum, E. faecalis, E. aerogenes, P. aeruginosa, C. sakazakii, E.coli, K. pneumonia, hospital Streptococcus spp., C. albicans and A. niger in 100, 500 g/mL and 100 g/disk. Substances exhibited moderate toxicity in 0.025, 0.1 and 0.25 mg/mL in bioluminescence inhibition tests of Photobacterium leiognathi. SAR exposed that introduction of 2,4-(Cl)2C6H3-, 2,5-(OMe)2C6H3-, 4-Me-2-iPr-C6H3O- and 3-iPr-C6H4O- fragments and reduction of the pyrimidine ring of R-([1,2,4]triazolo[1,5-c]quinazolin-2-ylthio)alcohols were the best modifications to promote antimicrobial activity. Molecular docking showed their good affinity into the active sites of EcPanK-AMPPNP and hDHFR. Hence, reported results will be used for subsequent QSAR model creation and purposeful antimicrobial modification of the strongest compounds.

Loading Zaporizhzhya State Medical University collaborators
Loading Zaporizhzhya State Medical University collaborators